Thursday, June 23, 2011

Pfizer's virtual trial: Open-source meets old pharma

Pfizer's virtual trial: Open-source meets old pharma
By gmiller
Created Jun 21 2011 - 12:02am
CHICAGO -- Drug giant Pfizer revealed more details of its all-electronic clinical trial [1] at the DIA's 47th annual show here, going to great lengths to acknowledge its partners in the endeavor and to credit collaboration for the achievements to date.
The news sounds big coming from a big pharma, especially given that the FDA is onboard. Pfizer's head of clinical innovation Craig Lipset took pains to appreciate the regulatory and Institutional Review Board input his project has received. And he acknowledged the contributions of partners Steven Cummings of Mytrus, which provided the front-end tech build-out of the investigator sites; Cameron Robertson, business development manager at Exco intouch, provider of the mobile e-diary equipment; Perceptive Informatics, for its back-end technology work; and the University of California investigational team.
"It's hardly Pfizer's technology," said Lipset, sounding less like a Big Pharma practitioner and more like an open source advocate. "We don't believe Pfizer owns this approach. We want to see greater uptake in the wider community." He said he believes the model can scale internally and perhaps eventually be used as modules in conventional studies in a form of "disruptive new medicine."
His words are strikingly similar to those of Tomasz Sablinski, head of clinical development at private equity concern Celtic Therapeutics, in a FierceBiotech IT interview [2] last February: "If you want to introduce disruptive [technology], you have to go out on your own," he said. "You can't do it from within." Sablinski in his spare time is launching Transparency Life Sciences, an open-source drug development enterprise.
Both Sablinski and Lipset acknowledge the great contribution to be made by telemedicine, with apps that are "growing at the speed of light" yet rarely used in pharma [Sablinski], and an "app store of tools from telemedicine, which can help expand health IT connectivity." [Lipset] sees the use of telemedicine apps in clinical trials as "a repurposing rather than inventing." On the innovation behind his project, Lipset says, "there are two approaches a company like Pfizer can take. One is private, to hide it. We took the more challenging way--with qualification, regulators, the IRB. They're all partners now."
Sablinski for the most part agrees with Lipset. But he has one quibble: "Pfizer concocted the trial in secrecy; the old way." He implies the drug giant worked on the effort for months internally before reaching out to others. To extrapolate what Pfizer did to a truly transparent model, the drugmaker would have spoken up earlier and said to the larger community of stakeholders, "we want to conduct an all-electronic trial. How do we design it?"
But he's not complaining. "For me, [the Pfizer project] is a godsend." If it succeeds, it validates his concept for the fledgling open-source Transparency Life Sciences. - George Miller (email [3])


Monday, April 25, 2011

ALS Study Shows Social Media's Value as Research Tool

This article published in today's WSJ provides an important support for a new paradigm in clinical development. Although there were significant shortcomings, which would be obvious to anyone familiar with drug development process, the table at the end of the story is self explanatory. It does not take a financial guru to see what the advantage will be if you manage to save so much time and money in the process as this trial achieved, while introducing proper scientific scrutiny. This is what Transparency Life Sciences is about.



http://online.wsj.com/article/SB10001424052748704489604576283010994997034.html?mod=djemHL_t

Tuesday, April 5, 2011

Fierce Biotech on Transparency LS: Necessity driving leery pharma "open"

April 4, 2011 — 7:30am ET | By George Miller 

Read more: Necessity driving leery pharma "open" - FierceBiotechIT http://www.fiercebiotechit.com/story/necessity-driving-leery-pharma-open/2011-04-04?utm_medium=nl&utm_source=internal#ixzz1IeSnbDHB 

Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechITPHOENIX -- It's almost as if the topic were taboo: the open-source concept in drug development gets little play in the agenda at the Partnerships in Clinical Trials conference. The topic had a way of coming up, though.
When it comes to open-source drug R&D, "the clinical side is the conservative side," says Ken Getz, senior research fellow at the Tufts Center for the Study of Drug Development. But the downturn in the economy has stimulated thinking among big pharmas.
"A cultural shift is happening as companies downsize in some cases," he says. Success in open-source development efforts, perhaps first in translational medicine, "will lead to changes that are profound," says Getz.
Let's hope so. "This is an industry in deep, deep crisis," says Tomasz Sablinski, managing director at Celtic Therapeutics and the chief force behind Transparency Life Sciences, a fledgling open-source drug development enterprise. "It's not going to be saved by tweaking."
He says pharma's increasing use of outsourcing is merely a shifting of money within the same financially inefficient system. "Pharma is unhappy now; CROs are happy," he says. "CROs will become unhappy."
Sablinsky's open-source idea, as we've reported, involves contributions of compounds, computer code and drug development expertise as well as collaborations with patient-engagement web sites like Cure Together and use of telemedicine apps for clinical trial monitoring.
Clearly the idea is gaining some traction in drug development. Open-source clinical trial software OpenClinica, maintained by Akaza Research, now boasts more than 11,000 users. That's a 10-percent rise from last July, when the company announced a three-fold increase over the previous two years. 


Read more: Necessity driving leery pharma "open" - FierceBiotechIT http://www.fiercebiotechit.com/story/necessity-driving-leery-pharma-open/2011-04-04?utm_medium=nl&utm_source=internal#ixzz1IeSOkUv6
Subscribe: http://www.fiercebiotechit.com/signup?sourceform=Viral-Tynt-FierceBiotechIT-FierceBiotechIThttp://www.fiercebiotechit.com/story/necessity-driving-leery-pharma-open/2011-04-04?utm_medium=nl&utm_source=internal

Monday, March 14, 2011

Nature Biotech on crowdsourcing

a very good overview of current applications and outlook for the future... sadly only available to the subscribers...

The power of many

Nature Biotechnology
 
29,
 
201–203
 
(2011)
 
doi:10.1038/nbt.1792
Published online
 
Applications of crowdsourcing in commercial biotech remain few and far between, but the approach is proving increasingly popular for solving challenges in basic research. Clare Sansom reports.